. 2013 Dec 14;76(2):401–430. doi: 10.1007/s11538-013-9925-3

Table 4.

Overview of fitted parameters and distributions for NHL-B2 and RICOVER-60. The heterogeneity of the parameters is either on a patient-level, therapy-level, or study-level (see text). The standard deviation for tumour growth rate α distribution is not explicitly specified but is a result of the maximum entropy condition

Fitted parameter distribution	Heterogeneity	Distribution parameters prescribed (constraints for max. ent.)	Fitted value	5/95 %-Percentile	Remark
Tumour growth rate α	patient specific	expectation	0.118	[0.039,0.216]	fitted
Tumour growth rate α	patient specific	standard deviation	0.054	[0.039,0.216]	result of max. entr. cond.
Immunogenicity ρ	patient specific	expectation	0.078	[0.022,0.145]	fitted
Immunogenicity ρ	patient specific	standard deviation	0.038	[0.022,0.145]	fitted
log10(tumour volume T _diag)	patient specific	expectation	11.31	[10.5,12]	fitted
log10(tumour volume T _diag)	patient specific	standard deviation	0.47	[10.5,12]	est. from data
Chemosensitivity k _T	patient & therapy specific	expectation	2.36	[1.86,3.0]	fitted
Chemosensitivity k _T	patient & therapy specific	standard deviation	0.31	[1.86,3.0]	fitted
Effector tox k _E	therapy specific	single parameter	0.48		fitted
dose exponent tum. cells e _T	therapy specific	single parameter	0.80		fitted
Dose exponent eff. cells e _E	therapy specific	single parameter	2.44		fitted
Prop. hazard factor lhr	study specific	single parameter	0.164		fitted